Further scientific research is needed to investigate the role of CDK4/6 inhibitors in high-risk ER(+) patients, the addition of pertuzumab and TDM-1 in HER2-enriched subsets, and immunotherapy in the neoadjuvant treatment of BC patients. Here, CDK4 is linked to breast cancer.